Perlmutter Cancer Center

The purpose of the trial is to determine the safety and efficacy of the drug called XL184 (Cabozantinib) in people with sarcomas, Wilms tumor or other rare tumors that have come back or have not responded to other treatments. XL184 is an experimental drug. XL184 has been Food and Drug Administration (FDA) approved for the treatment of adults with progressive, metastatic medullary thyroid cancer and adults with advanced renal cell carcinoma who have received prior anti-angiogenic therapy. However, the use of XL184 in children and young adults with the types of cancer included in this trial has not yet been approved by the FDA and is considered experimental. In this trial, we want to learn the side effects of XL184 and how XL184 works against cancer cells and other immune cells.